HK1012338A1 - Sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-n-oxides process for their preparation and their use as medicaments - Google Patents

Sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-n-oxides process for their preparation and their use as medicaments

Info

Publication number
HK1012338A1
HK1012338A1 HK98113425A HK98113425A HK1012338A1 HK 1012338 A1 HK1012338 A1 HK 1012338A1 HK 98113425 A HK98113425 A HK 98113425A HK 98113425 A HK98113425 A HK 98113425A HK 1012338 A1 HK1012338 A1 HK 1012338A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
opt
bond
substd
pyridine
Prior art date
Application number
HK98113425A
Other languages
English (en)
Inventor
Klaus Weidmann
Martin Bickel
Volkmar Gunzler Pukall
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of HK1012338A1 publication Critical patent/HK1012338A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
HK98113425A 1994-03-25 1998-12-15 Sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-n-oxides process for their preparation and their use as medicaments HK1012338A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4410423A DE4410423A1 (de) 1994-03-25 1994-03-25 Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
HK1012338A1 true HK1012338A1 (en) 1999-07-30

Family

ID=6513863

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98113425A HK1012338A1 (en) 1994-03-25 1998-12-15 Sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-n-oxides process for their preparation and their use as medicaments

Country Status (20)

Country Link
US (1) US5610172A (fr)
EP (1) EP0673931B1 (fr)
JP (1) JPH07278109A (fr)
KR (1) KR950032124A (fr)
CN (1) CN1114312A (fr)
AT (1) ATE156815T1 (fr)
AU (1) AU689199B2 (fr)
CA (1) CA2145476A1 (fr)
CZ (1) CZ287768B6 (fr)
DE (2) DE4410423A1 (fr)
DK (1) DK0673931T3 (fr)
ES (1) ES2105798T3 (fr)
FI (1) FI951386A (fr)
GR (1) GR3024860T3 (fr)
HK (1) HK1012338A1 (fr)
HU (1) HUT72059A (fr)
NO (1) NO304308B1 (fr)
NZ (1) NZ270783A (fr)
PL (1) PL180042B1 (fr)
ZA (1) ZA952408B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191368B1 (en) 1995-09-12 2001-02-20 Tessera, Inc. Flexible, releasable strip leads
CN102526044A (zh) 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
EP2295060B1 (fr) 2001-12-06 2018-10-31 Fibrogen, Inc. Traitement de conditions ischémiques ou hypoxiques
US20040158289A1 (en) * 2002-11-30 2004-08-12 Girouard Steven D. Method and apparatus for cell and electrical therapy of living tissue
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US8060219B2 (en) * 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
AU2007232607B2 (en) * 2006-03-30 2010-09-16 Lg Electronics Inc. A method and apparatus for decoding/encoding a video signal
EP2044005B8 (fr) 2006-06-26 2012-12-05 Warner Chilcott Company, LLC Inhibiteurs de la prolyl hydroxylase et procédés d'utilisation
WO2009002533A1 (fr) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Thérapies d'affection abdominale inflammatoire
NO2686520T3 (fr) 2011-06-06 2018-03-17
EP3007695B1 (fr) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions et méthodes de traitement de l'anémie
MA39033A1 (fr) 2013-11-15 2017-11-30 Akebia Therapeutics Inc Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
DK3277270T3 (da) 2015-04-01 2021-12-06 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
CZ287768B6 (en) 2001-01-17
ZA952408B (en) 1995-11-27
HUT72059A (en) 1996-03-28
EP0673931A1 (fr) 1995-09-27
CA2145476A1 (fr) 1995-09-26
DE4410423A1 (de) 1995-09-28
PL307848A1 (en) 1995-10-02
CZ73395A3 (en) 1995-11-15
PL180042B1 (en) 2000-12-29
ATE156815T1 (de) 1997-08-15
EP0673931B1 (fr) 1997-08-13
FI951386A0 (fi) 1995-03-23
HU9500865D0 (en) 1995-05-29
DK0673931T3 (da) 1998-03-16
US5610172A (en) 1997-03-11
AU689199B2 (en) 1998-03-26
KR950032124A (ko) 1995-12-20
NO951146L (no) 1995-09-26
ES2105798T3 (es) 1997-10-16
DE59500488D1 (de) 1997-09-18
JPH07278109A (ja) 1995-10-24
AU1504295A (en) 1995-10-05
NO951146D0 (no) 1995-03-24
NO304308B1 (no) 1998-11-30
FI951386A (fi) 1995-09-26
CN1114312A (zh) 1996-01-03
GR3024860T3 (en) 1998-01-30
NZ270783A (en) 1997-02-24

Similar Documents

Publication Publication Date Title
HK1012338A1 (en) Sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-n-oxides process for their preparation and their use as medicaments
GR3033706T3 (en) Sulfonamidocarbonyl-pyridine-2-carboxamides as well as their pyridine-N-oxides, process for their preparation and their use as medicaments.
US4889931A (en) Manganese (II) chelate manufacture
MY103963A (en) Isoquinoline derivatives, their preparation and their use
ZA903804B (en) A method of potentiating cell-mediated immunity utilizing polyamine derivatives
IE882365L (en) Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
US4978763A (en) Novel manganese(II) DTPA chelate
EP0255807A3 (en) N-alkylamides of d-(+) -carnitine having antibacterial activity, process for their preparation and pharmaceutical and cosmetic compositions containing same
PT84814A (en) 3-hydroxypyridines
JPH0481594B2 (fr)
CA2268166A1 (fr) Derives de pyrrolo[3,2-c]quinoline contenant un groupe haloalcoxy et leurs els pharmaceutiquement acceptables
ZA905799B (en) Control of scale in aqueous systems using certain phosphonomethyl amine oxides
HUT72090A (en) Positive inotropic and lusitropic pyrroloquinolinone derivatives, pharmaceutical compositions containing them and process for their production
PL312240A1 (en) Novel 3-alkoxycarbonyl-thiadiazinones, method of obtaining them and pharmaceutical preparation and method of obtaining same

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20040313

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)